PE20142305A1 - Compuestos de n-ariltriazol como antagonistas de lpar - Google Patents

Compuestos de n-ariltriazol como antagonistas de lpar

Info

Publication number
PE20142305A1
PE20142305A1 PE2014002213A PE2014002213A PE20142305A1 PE 20142305 A1 PE20142305 A1 PE 20142305A1 PE 2014002213 A PE2014002213 A PE 2014002213A PE 2014002213 A PE2014002213 A PE 2014002213A PE 20142305 A1 PE20142305 A1 PE 20142305A1
Authority
PE
Peru
Prior art keywords
compounds
arylthriazole
lpar
antagonists
triazol
Prior art date
Application number
PE2014002213A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20142305A1 publication Critical patent/PE20142305A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2014002213A 2012-06-20 2013-06-17 Compuestos de n-ariltriazol como antagonistas de lpar PE20142305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
PE20142305A1 true PE20142305A1 (es) 2015-01-16

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002213A PE20142305A1 (es) 2012-06-20 2013-06-17 Compuestos de n-ariltriazol como antagonistas de lpar

Country Status (22)

Country Link
US (1) US20150133512A1 (pt-PT)
EP (1) EP2864301A1 (pt-PT)
JP (1) JP2015520203A (pt-PT)
KR (1) KR20150011389A (pt-PT)
CN (1) CN104395299A (pt-PT)
AU (1) AU2013279513A1 (pt-PT)
BR (1) BR112014030674A2 (pt-PT)
CA (1) CA2869564A1 (pt-PT)
CL (1) CL2014003241A1 (pt-PT)
CO (1) CO7131357A2 (pt-PT)
EA (1) EA201492281A1 (pt-PT)
HK (1) HK1206339A1 (pt-PT)
IL (1) IL236087A0 (pt-PT)
IN (1) IN2014DN09352A (pt-PT)
MA (1) MA37762B1 (pt-PT)
MX (1) MX2014014711A (pt-PT)
PE (1) PE20142305A1 (pt-PT)
PH (1) PH12014502363A1 (pt-PT)
SG (1) SG11201407228PA (pt-PT)
UA (1) UA110310C2 (pt-PT)
WO (1) WO2013189865A1 (pt-PT)
ZA (1) ZA201408167B (pt-PT)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140067048A (ko) 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
AU2014232383B2 (en) 2013-03-15 2019-01-17 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
CN111479807A (zh) * 2017-12-19 2020-07-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑吖嗪
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR20200100719A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
ES2925626T3 (es) 2017-12-19 2022-10-19 Bristol Myers Squibb Co Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
EA202091505A1 (ru) 2017-12-19 2020-09-22 Бристол-Маерс Сквибб Компани Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
SG11202005701VA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3728222B1 (en) 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3218917A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
AU2011338561A1 (en) * 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
KR20140067048A (ko) * 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
CN104411692A (zh) * 2012-06-20 2015-03-11 霍夫曼-拉罗奇有限公司 作为lpar拮抗剂的n-烷基三唑化合物

Also Published As

Publication number Publication date
BR112014030674A2 (pt) 2017-06-27
MA37762B1 (fr) 2018-04-30
MX2014014711A (es) 2015-03-04
EA201492281A1 (ru) 2015-04-30
IL236087A0 (en) 2015-02-01
KR20150011389A (ko) 2015-01-30
EP2864301A1 (en) 2015-04-29
CL2014003241A1 (es) 2015-03-20
US20150133512A1 (en) 2015-05-14
PH12014502363A1 (en) 2015-01-12
HK1206339A1 (en) 2016-01-08
MA37762A1 (fr) 2017-07-31
JP2015520203A (ja) 2015-07-16
CA2869564A1 (en) 2013-12-27
CN104395299A (zh) 2015-03-04
IN2014DN09352A (pt-PT) 2015-07-17
ZA201408167B (en) 2015-12-23
SG11201407228PA (en) 2014-12-30
WO2013189865A1 (en) 2013-12-27
UA110310C2 (uk) 2015-12-10
CO7131357A2 (es) 2014-12-01
AU2013279513A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
PE20142305A1 (es) Compuestos de n-ariltriazol como antagonistas de lpar
PE20142448A1 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
PE20190211A1 (es) Acidos de carbamoiloximetil triazol ciclohexilo como antagonistas de acido lisofosfatidico (lpa)
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
PE20150974A1 (es) Derivados de piridina
PE20141607A1 (es) Compuestos heterociclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparacion
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
PE20160846A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c
UY32736A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
PE20141789A1 (es) Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
BR112015003998A2 (pt) compostos de cianopirazol lpar-substituídos
BR112013028197A2 (pt) compostos de benzofurano-piperidina
PE20141121A1 (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmaceuticos
CU20130159A7 (es) Derivados de la piperidina 3- espirocíclica como agonistas de receptores de la ghrelina
BR112017013731A2 (pt) composto heterocíclico selecionado dentre os compostos de fórmula geral, composição farmacêutica, e, uso cosmético de um composto de fórmula geral

Legal Events

Date Code Title Description
FD Application declared void or lapsed